The CYP171A1 inhibitor abiraterone, which blocks androgen synthesis, was approved for advanced-stage prostate cancer, and the BRAF inhibitor vemurafenib was approved for metastatic melanoma with the BRAF V600E mutation. Here, BRAF is linked to Familial prostate cancer.